ENTX
Price:
$2.175
Market Cap:
$80.11M
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Ente...[Read more]
Industry
Biotechnology
IPO Date
2018-06-28
Stock Exchange
NASDAQ
Ticker
ENTX
According to Entera Bio Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -8.37. This represents a change of 37.92% compared to the average of -6.07 of the last 4 quarters.
The mean historical PE Ratio of Entera Bio Ltd. over the last ten years is -9.28. The current -8.37 PE Ratio has changed 8.92% with respect to the historical average. Over the past ten years (40 quarters), ENTX's PE Ratio was at its highest in in the March 2016 quarter at 6.41. The PE Ratio was at its lowest in in the December 2016 quarter at -15.71.
Average
-9.28
Median
-2.39
Minimum
-44.90
Maximum
-1.61
Discovering the peaks and valleys of Entera Bio Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 203.51%
Maximum Annual PE Ratio = -1.61
Minimum Annual Increase = -89.29%
Minimum Annual PE Ratio = -44.90
Year | PE Ratio | Change |
---|---|---|
2023 | -1.96 | 21.70% |
2022 | -1.61 | -73.39% |
2021 | -6.05 | 203.51% |
2020 | -1.99 | -16.61% |
2019 | -2.39 | 1.47% |
2018 | -2.35 | -51.03% |
2017 | -4.81 | -89.29% |
2016 | -44.90 | 157.36% |
The current PE Ratio of Entera Bio Ltd. (ENTX) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.20
5-year avg
-2.80
10-year avg
-9.28
Entera Bio Ltd.’s PE Ratio is greater than NLS Pharmaceutics AG (-38.93), less than Vaccinex, Inc. (-0.13), less than Alterity Therapeutics Limited (-1.52), less than Enochian Biosciences, Inc. (-1.98), greater than Immutep Limited (-15.18),
Company | PE Ratio | Market cap |
---|---|---|
-38.93 | $4.68M | |
-0.13 | $3.16M | |
-1.52 | $21.72M | |
-1.98 | $45.38M | |
-15.18 | $304.51M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Entera Bio Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Entera Bio Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Entera Bio Ltd.'s PE Ratio?
How is the PE Ratio calculated for Entera Bio Ltd. (ENTX)?
What is the highest PE Ratio for Entera Bio Ltd. (ENTX)?
What is the 3-year average PE Ratio for Entera Bio Ltd. (ENTX)?
What is the 5-year average PE Ratio for Entera Bio Ltd. (ENTX)?
How does the current PE Ratio for Entera Bio Ltd. (ENTX) compare to its historical average?